DE69822295D1 - Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen - Google Patents

Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen

Info

Publication number
DE69822295D1
DE69822295D1 DE69822295T DE69822295T DE69822295D1 DE 69822295 D1 DE69822295 D1 DE 69822295D1 DE 69822295 T DE69822295 T DE 69822295T DE 69822295 T DE69822295 T DE 69822295T DE 69822295 D1 DE69822295 D1 DE 69822295D1
Authority
DE
Germany
Prior art keywords
misoprostol
erectional
disorders
treatment
misoprostolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69822295T
Other languages
English (en)
Other versions
DE69822295T2 (de
Inventor
Panagiotis Kanakaris
Petros Athens Karouzakis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69822295D1 publication Critical patent/DE69822295D1/de
Publication of DE69822295T2 publication Critical patent/DE69822295T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69822295T 1997-05-06 1998-04-22 Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen Expired - Fee Related DE69822295T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR97100172 1997-05-06
GR97100172 1997-05-06
PCT/GR1998/000012 WO1998050039A1 (en) 1997-05-06 1998-04-22 Use of misoprostol or/and misoprostol acid for preparing drug in order to cure erectile dysfunction

Publications (2)

Publication Number Publication Date
DE69822295D1 true DE69822295D1 (de) 2004-04-15
DE69822295T2 DE69822295T2 (de) 2005-02-24

Family

ID=10942965

Family Applications (2)

Application Number Title Priority Date Filing Date
DE0980245T Pending DE980245T1 (de) 1997-05-06 1998-04-22 Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen
DE69822295T Expired - Fee Related DE69822295T2 (de) 1997-05-06 1998-04-22 Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE0980245T Pending DE980245T1 (de) 1997-05-06 1998-04-22 Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen

Country Status (10)

Country Link
US (2) US6210343B1 (de)
EP (1) EP0980245B1 (de)
JP (1) JP2001525803A (de)
AT (1) ATE261307T1 (de)
AU (1) AU6848098A (de)
DE (2) DE980245T1 (de)
ES (1) ES2216279T3 (de)
GR (1) GR1002847B (de)
PT (1) PT980245E (de)
WO (1) WO1998050039A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US7087240B1 (en) * 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
GR1003199B (el) 1998-08-14 1999-09-01 Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US7176238B1 (en) 1999-03-01 2007-02-13 Nitromed Inc. Nitrostated and nitrosylated prostaglandins, compositions and methods of use
US7479120B2 (en) * 2002-02-22 2009-01-20 Hans Gregersen Method and apparatus for investigating force-deformation properties in muscles in walls of bodily hollow systems
US8287474B1 (en) 2002-08-22 2012-10-16 Koenig J Frank Method and apparatus for noninvasively increasing whole body blood flow and noninvasive physical exercise of limbs from the outside and from within the limb to treat diseases throughout the body
US7037257B1 (en) 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20050255161A1 (en) * 2004-05-10 2005-11-17 Servet Buyuktimkin Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060286172A1 (en) * 2005-06-03 2006-12-21 Anu Mahashabde Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
JP2010095454A (ja) * 2008-10-14 2010-04-30 Cyclochem:Kk 抗菌組成物
US20100184722A1 (en) * 2008-12-19 2010-07-22 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
RU2444989C1 (ru) * 2010-09-27 2012-03-20 Государственное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России) Способ диагностики васкулогенной эректильной дисфункции
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
IT201600119871A1 (it) * 2016-11-25 2018-05-25 Sabatino Russo Uso dell’associazione di inibitori della fosfodiesterasi 5 con prostaglandina e1 per il trattamento della disfunzione erettile
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4696821A (en) 1983-10-11 1987-09-29 Warner-Lambert Company Transdermal delivery system for administration of nitroglycerin
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
ATE173603T1 (de) 1990-04-25 1998-12-15 Vivus Inc Behandlung von erektionversagen
WO1993000894A1 (en) * 1991-07-03 1993-01-21 Scott Nathan E Prostaglandin e2 treatment of impotence
US5962528A (en) 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US5252602A (en) * 1991-10-11 1993-10-12 Rafeul Alam Effects of misoprostol on allergic responses
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
US5324746A (en) * 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US6007836A (en) 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
FR2710649A1 (fr) 1993-09-30 1995-04-07 Germinal Sarl Film polymérique à base de prolamines, son procédé de préparation et ses applications .
US6013277A (en) 1994-08-05 2000-01-11 Inpharma S.A. Compositions for topical treatment of erectile impotence
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
CN1126587A (zh) 1995-01-10 1996-07-17 王怀秀 经阴囊睾酮缓释系统
PL322268A1 (en) 1995-03-14 1998-01-19 Vivus Inc Method of and device for avoiding penile erection disorders
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5688499A (en) 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
US5684177A (en) 1996-05-17 1997-11-04 Torcan Chemical Ltd. Misoprostol
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
CA2306837C (en) 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6277884B1 (en) 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
AU1414200A (en) 1998-12-02 2000-06-19 Mochida Pharmaceutical Co., Ltd. Preparations for intraurethral administration
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
CA2403686C (en) 2000-03-23 2010-01-26 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
US6476037B1 (en) 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
US6472398B1 (en) 2000-03-23 2002-10-29 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2416709A1 (en) 2000-07-31 2003-01-17 Ono Pharmaceutical Co., Ltd. Therapeutic agent for erectile dysfunction containing as the active ingredient prostaglandin derivatives

Also Published As

Publication number Publication date
DE69822295T2 (de) 2005-02-24
WO1998050039A1 (en) 1998-11-12
DE980245T1 (de) 2000-08-31
EP0980245A1 (de) 2000-02-23
US6589990B1 (en) 2003-07-08
GR1002847B (el) 1998-01-27
PT980245E (pt) 2004-06-30
US6210343B1 (en) 2001-04-03
JP2001525803A (ja) 2001-12-11
ES2216279T3 (es) 2004-10-16
ATE261307T1 (de) 2004-03-15
EP0980245B1 (de) 2004-03-10
AU6848098A (en) 1998-11-27

Similar Documents

Publication Publication Date Title
DE69822295D1 (de) Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen
ES2052733T3 (es) Dispositivo electroterapeutico de baja frecuencia.
DE69617469D1 (de) Behandlung von multipler sklerose
DE69428523D1 (de) Verfahren zur behandlung von gemüts- oder geisteskrankheiten und von gemüts- oder geisteskrankheiten, die von anfällen begleitet sind
EA199800694A1 (ru) Композиция, включающая ингибитор il-1 и гидрогелевый эфир, и способы ее применения
EA200001044A2 (ru) Соединения для лечения женской сексуальной дисфункции
ATE406176T1 (de) Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
ES2191068T3 (es) Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel.
EA199700213A1 (ru) Крем на водной основе для локального применения, способ его приготовления, способ лечения эректильной дисфункции у мужчин, способ лечения аноргазма у женщин, способ лечения микроваскулярных заболеваний и способ лечения ран или хирургических рассечений
LU91125I2 (fr) Ranélate den strontium et ses dérivés pharmaceutiquement acceptables (protelos).
ATE233091T1 (de) Verwendung von histamine-2 agonisten zur behandlung sexueller funktionsstörungen
DE69227306D1 (de) Behandlung von zellgewebsentzündung mit retinoide
DE69528602D1 (de) Prophylaktische behandlung der allergischen kontaktdermatitis
ATE138567T1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
PT1007093E (pt) Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
EP0279867A3 (de) Verwendung von Vitamin-E und Vitamin-E-Kombination mit nichtsteroidalen Antirheumatika und Schmerzmittel zur Behandlung von rheumatischen Erkrankungen
Downey et al. Combined short contact crude coal tar and dithranol therapy for psoriasis
RU2089241C1 (ru) Способ лечения хронической венозной недостаточности нижних конечностей у больных остеоартрозом
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
SU1715358A1 (ru) Способ лечени дерматитов
RU93057223A (ru) Способ лечения параличей и парезов
Alexander et al. Experience of emplying extracorporal shock-wave therapy for treating limb enthesopathies in patients with articular hypermobility syndrome
UA37370A (uk) Спосіб прогнозування ефективності монотерапії антагоністами кальцію під час лікування гіпертонічної хвороби

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee